Displaying 26–50 of 75 results for Patheon
This white paper, first in a series of three, is to help executives and managers assigned to provide due-diligence of prospective contract manufacturing partners a framework in which to make a solid, objective evaluation of its overall operational excellence as it relates to quality.
Winning projects for 2014 were selected from 27 well-qualified entries
Pharmaceutical manufacturing capacity is increasingly global and going biologic, but challenged to meet the realities of cGMP
$2.65 billion transaction combines the capabilities and expertise of Patheon and DSM Pharmaceutical Products to create industry powerhouse
DCAT Week '14, held March 10-14 in NYC, will address quality by design in a session titled, Quality by Design: Client, Contractor, and Regulatory Perspectives with Case Studies.
Inline cooling to reduce temperatures at tablet compression offers relief from this sticky issue.
Leading contract service organizations discuss operations and strategies driving success.
WellSpring appoints Lonnie Barish, MBA, as executive director of business development, and David Watt as technical director, pharma services
Royal DSM has confirmed that its biologics manufacturing operations and new Australian facility will be part of the business merged with Patheon in its agreement with JLL.
Clearly articulating its long-term strategic and global interest in biologics, last October DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, officially announced opening of its new cGMP facility for biopharmaceutical contract manufacturing in Brisbane, ...
Expected 2014 sales of about $2 billion
The new company anticipates 2014 sales of about $2 billion
Best practices for one of oursourced manufacturing's tougher challenges
Patheon acquires Banner Pharmacaps to build scale, expand capacity and broaden footprint in emerging markets
At Interphex 2012, Patheon's Geoffrey Glass and Softigel's Alvaro Franco discuss their companies' new collaboration to offer customers P-Gels, or prescription softgels and other new technologies that have not previously been available within pharmaceutical contract manufacturing. New, innovative ...
The global market for pharmaceutical contract manufacturing witnessed robust growth in recent years, and the future continues to hold tremendous prospects for the industry.
Contract drug developer Patheon said Wednesday it has let president and chief executive Wesley Wheeler go. Company chairman Ramsey Frank said Patheon has reached a stage where new leadership is required to realize its full potential. Peter Bigelow, president of Patheon's North American ...
Two five-year manufacturing agreements extend the partnership between the two companies.
Big Pharma has gone green, but smaller manufacturers have yet to flip the switch, say industry experts and our own survey.
Can the act of quantifying and promising results for customers, and taking a hit if theyre not met, actually improve ones own performance?
Patheons metrics have improved to the point that it is incorporating on-time delivery guarantees and other new wrinkles into its contracts.